Related references
Note: Only part of the references are listed.Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation
Talita M. Marin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The Face of Noonan Syndrome: Does Phenotype Predict Genotype
Judith E. Allanson et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload
Norifumi Takeda et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation
Peng-Chieh Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
A restricted spectrum of NRAS mutations causes Noonan syndrome
Ion C. Cirstea et al.
NATURE GENETICS (2010)
Molecular targets and regulators of cardiac hypertrophy
Rohini Agrawal et al.
PHARMACOLOGICAL RESEARCH (2010)
Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back
Katherine A. Rauen et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2009)
Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis
Gordon Chan et al.
BLOOD (2009)
Cardiomyocyte-Specific Loss of Neurofibromin Promotes Cardiac Hypertrophy and Dysfunction
Junwang Xu et al.
CIRCULATION RESEARCH (2009)
The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation
William E. Tidyman et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2009)
Cardiac Fibroblasts Regulate Myocardial Proliferation through β1 Integrin Signaling
Masaki Leda et al.
DEVELOPMENTAL CELL (2009)
Malignant Diseases in Noonan Syndrome and Related Disorders
Henrik Hasle
HORMONE RESEARCH (2009)
Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling
Kristina Lorenz et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Hypertrophic cardiomyopathy: current understanding and treatment objectives
G. S. Soor et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair
Viviana Cordeddu et al.
NATURE GENETICS (2009)
Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene
Xu Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations
Tomoki Nakamura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation
Toshiyuki Araki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Stephen D. Barrett et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
The tyrosine phosphatase Shp2 (PTPN11) in cancer
Gordon Chan et al.
CANCER AND METASTASIS REVIEWS (2008)
The RAS/MAPK syndromes: Novel roles of the RAS pathway in human genetic disorders
Yoko Aoki et al.
HUMAN MUTATION (2008)
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thomas Thum et al.
NATURE (2008)
Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome
Maike Krenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo
Nicole H. Purcell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Germline gain-of-function mutations in RAF1 cause Noonan syndrome
M. Abdur Razzaque et al.
NATURE GENETICS (2007)
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy
Bhaswati Pandit et al.
NATURE GENETICS (2007)
Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome
Tomoki Nakamura et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome
Karen W. Gripp et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2007)
The spectrum of cardiac anomalies in Noonan syndrome as a result of mutations in the PTPN11 gene
Yves Sznajer et al.
PEDIATRICS (2007)
Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations
Martin Zenker et al.
JOURNAL OF MEDICAL GENETICS (2007)
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome
Marco Tartaglia et al.
NATURE GENETICS (2007)
Germline gain-of-function mutations in SOS1 cause Noonan syndrome
Amy E. Roberts et al.
NATURE GENETICS (2007)
Regulation of cardiac hypertrophy by intracellular signalling pathways
Joerg Heineke et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: Consequences for PI3K binding on Gab1
Nadine Hanna et al.
FEBS LETTERS (2006)
Electrotonic modulation of cardiac impulse conduction by myofibroblasts
M Miragoli et al.
CIRCULATION RESEARCH (2006)
Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation
S Mitchell et al.
PHYSIOLOGICAL GENOMICS (2006)
PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects
MI Kontaridis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome
P Rodriguez-Viciana et al.
SCIENCE (2006)
Germline KRAS mutations cause Noonan syndrome
S Schubbert et al.
NATURE GENETICS (2006)
Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome
T Niihori et al.
NATURE GENETICS (2006)
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
M Tartaglia et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
HRAS mutation analysis in Costello syndrome: Genotype and phenotype correlation
KW Gripp et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2006)
Germline mutations in HRAS proto-oncogene cause Costello syndrome
Y Aoki et al.
NATURE GENETICS (2005)
Does load-induced ventricular hypertrophy progress to systolic heart failure?
K Berenji et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2005)
Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome - Natural history
RT Murphy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Shp2 regulates Src family kinase activity and Ras/Erk activation by controlling Csk recruitment
SQ Zhang et al.
MOLECULAR CELL (2004)
Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload
IS Harris et al.
CIRCULATION (2004)
Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation
T Araki et al.
NATURE MEDICINE (2004)
Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism
EE Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart
MZ Zheng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation
DR Bertola et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2004)
Mutation analysis of AMP-activated protein kinase subunits in inherited cardiomyopathies: implications for kinase function and disease pathogenesis
SMJ Oliveira et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2003)
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement
IH Su et al.
NATURE IMMUNOLOGY (2003)
Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death
OF Bueno et al.
CIRCULATION RESEARCH (2002)
Leptin: a review of its peripheral actions and interactions
S Margetic et al.
INTERNATIONAL JOURNAL OF OBESITY (2002)
Prevention of hypertrophy by overexpression of Kv4.2 in cultured neonatal cardiomyocytes
C Zobel et al.
CIRCULATION (2002)
Hypertrophic cardiomyopathy - A systematic review
BJ Maron
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
M Tartaglia et al.
NATURE GENETICS (2001)
Mutations in the γ2 subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy:: evidence for the central role of energy compromise in disease pathogenesis
E Blair et al.
HUMAN MOLECULAR GENETICS (2001)
Divergent roles of SHP-2 in ERK activation by leptin receptors
C Bjorbæk et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The dual-specificity phosphatase MKP-1 limits the cardiac hypertrophic response in vitro and in vivo
OF Bueno et al.
CIRCULATION RESEARCH (2001)
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
OF Bueno et al.
EMBO JOURNAL (2000)
Share Paper
